Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor

Journal of Cardiovascular Pharmacology

Volumn 31, Issue SUPPL. 1, 1998, Pages

  Shetty, Suraj S ^a   Savage, Paula ^a   DelGrande, Dominick ^a   De Lombaert, Stéphane ^a   Jeng, Arco Y ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Big endothelin 1; CGS 31447; Endothelin 1; Endothelin converting enzyme; Perfused kidney

Indexed keywords

ASPARTIC PROTEINASE; CGS 31447; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN-CONVERTING ENZYME 1; METALLOPROTEINASE; PHOSPHONIC ACID DERIVATIVE; PROTEIN PRECURSOR; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; TETRAZOLE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; IN VITRO STUDY; KIDNEY; KIDNEY CIRCULATION; KINETICS; MALE; METABOLISM; PROTEIN BINDING; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BLOOD PRESSURE; ENDOTHELIN-1; ENDOTHELINS; HUMANS; KIDNEY; KINETICS; MALE; METALLOENDOPEPTIDASES; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RENAL CIRCULATION; TETRAZOLES;

EID: 0031639677     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800001-00022     Document Type: Article

References (10)

1. Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 1996; 72:261-90.
2. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85.
3. Emoto N, Yanagisawa M. Endothelin-converting enzyme is a membrane-bound, phosphoramidon sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995;270:15262-8.
4. De Lombaert S, Stamford LB, Blanchard L, et al. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1997;7:1059-64.
5. Trapani AJ, Balwierczak JL, Lappe RW, et al. Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelm-1. Biochem Mol Biol Int 1993;31:861-7.
6. Kaw S, Emoto N, Jeng A, Yanagisawa M. Pharmacological characterization of cloned human ECE-1 and ECE-2 [Abstract]. Proc 4th Int Conf Endothelin 1995;C6.
7. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-52.
8. Warner TD, Mitchell JA, DeNucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of rat and rabbit. J Cardiovasc Pharmacol 1989;13(suppl 5):S85-8.
9. Verbeuren TJ, Mennecier P, Merceron D, et al. Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys. J Cardiovasc Pharmacol 1993;22 (suppl 8):S81-4.
10. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-62.